<PAGE>
------------------------------------------------------------------------------
------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)JUNE 29,2000
Commission File Number 0-23252
IGEN INTERNATIONAL, INC.
(Exact name of registrant)
DELAWARE 94-2852543
(State of organization) (I.R.S. Employer
Identification No.)
16020 INDUSTRIAL DRIVE, GAITHERSBURG MARYLAND 20877
------------------------------------------------------------
(Address of principal executive offices and zip code)
(301) 869-9800
----------------------------------
(Registrant's telephone Number)
------------------------------------------------------------------------------
------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS
On June 29, 2000, the Board of Diretors of IGEN International, Inc. (the
"Company") appointed two new members: Richard W. Cass, Esq., and Anthony Rees,
D.Phil. These two members replace Edward B. Lurier and William J. O'Neill. Mr.
Cass was appointed to a term that expires in 2002 and Dr. Rees was appointed to
a term that expires in 2000.
Since 1979, Mr. Cass, (age 54) has been a partner with the law firm of Wilmer,
Cutler & Pickering, which serves as outside counsel to the company. He is a
member of his firm's Management Committee and co-chairman of its Corporate
Practice Group. He specializes in corporate and securities law and represents
companies and entrepreneurs in acquisitions, dispositions, joint ventures, and
public securities offerings. Mr. Cass received his bachelor's degree from
Princeton University and his law degree from Yale University.
Dr. Rees, 56, is Director of Science at Synt:em, a French biotechnology company,
and Professorial Research Fellow at the University of Bath, Great Britain. He is
Executive Editor of the journal PROTEIN ENGINEERING, has numerous patents, and
has published more than 110 peer-reviewed scientific papers and two books. While
on sabbatical from Oxford University from 1989 to 1990, Dr. Rees was Vice
President of Research at IGEN. He also co-founded the British software company
Oxford Molecular PLC. Among his past positions, he has been Head of the
Biochemistry Department at the University of Bath. He received his doctoral
degree from Oxford University.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IGEN INTERNATIONAL, INC.
By: /s/ Samuel J. Wohlstadter
------------------------------------
Samuel J. Wohlstadter
Chairman and Chief Executive Officer
Dated: June 29, 2000
